- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04713969
Neuro-immune Interactions and PPI
Duodenal Neuro-immune Interactions and Effects of PPI in Functional Dyspepsia
Study Overview
Detailed Description
Duodenal low-grade inflammation is frequently reported in functional dyspepsia (FD), while also neuronal and structural changes in duodenal submucosal ganglia have been described in FD patients. Proton pump inhibitors (PPI) are the first-line therapy in FD patients and are recently shown to have anti-inflammatory properties in FD. However, the exact mechanism of their anti-inflammatory action is unknow and their effect on duodenal nerve signalling remain unclear.
In this prospective interventional study, FD patients will undergo study procedures before and after treatment with pantoprazole (Pantomed®) 40mg twice daily during 4 weeks, with a baseline comparison to healthy volunteers.
This study aims to provide an in-deep characterization of the inflammatory infiltrate in the duodenum of FD patients, and to unravel the effect of PPI-therapy on neuronal signalling, duodenal inflammation and neuro-immune interactions in FD.
Novel insights in the pathophysiology of FD, including the duodenal mucosal inflammation and impaired neuronal functioning, can provide a better understanding of this commonly and costly disorder. Moreover, these results will help to elucidate the anti-inflammatory effect of PPI, which will contribute to the discovery of predictive markers for therapeutic efficacy of PPI in FD.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Tim Vanuytsel, MD PhD
- Phone Number: 32 16341973
- Email: Tim.vanuytsel@kuleuven.be
Study Contact Backup
- Name: Lucas Wauters, MD
- Phone Number: 32 16345238
- Email: lucas.wauters@kuleuven.be
Study Locations
-
-
Belgie
-
Leuven, Belgie, Belgium, 3000
- Recruiting
- KU Leuven
-
Contact:
- Tim Vanuytsel, MD PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with FD diagnosis as per Rome IV criteria (EPS or PDS).
- Normal investigation including upper GI endoscopy.
- Patients have confirmed duodenal mucosal eosinophilia.
- Patients witnessed written informed consent.
- Patients aged between 18 and 64 years inclusive.
- Male or female (not pregnant or lactating and using contraception or postmenopausal).
- Subjects are capable to understand the study and the questionnaires, and to comply with the study requirements.
Exclusion Criteria:
- Patients with any condition which, in the opinion of the investigator, makes the patient unsuitable for entry into the study.
- Patients with any major psychiatric disorders (stable dose of single antidepressant allowed for psychiatric indication, no limitation for other indications).
- Patients presenting with predominant symptoms of irritable bowel syndrome (IBS) or of gastro-esophageal reflux disease (GERD).
- Patients with personal or family (first-degree relative) of diabetes mellitus, celiac disease, inflammatory bowel disease, psoriasis, lupus, scleroderma, rheumatic or other systemic auto-immune disease.
- Patients with eosinophilic esophagitis or eosinophilic gastroenteritis.
- Active H. pylori infection (or <6 months after eradication).
- Allergy or atopy, including therapy.
- Organic gastro-intestinal disease or history of gastrointestinal surgery other than appendectomy or splenectomy.
- Known impaired liver or kidney dysfunction, or coagulation disorders.
- Known HIV, HBV or HCV infection, including therapy.
- Active coronary or peripheral artery disease.
- Use of anti-inflammatory drugs or anti-allergy drugs <2 weeks before sampling.
- Use of immunosuppressants, antibiotics or acid-suppressive drugs <3 months before sampling.
- Use of prokinetics <2 weeks before sampling (unless if ≤3/week).
- Significant alcohol use (>10 units/week).
- Any use of alcohol or smoking <2 days before sampling.
- Active malignancy, including therapy.
- Females who are pregnant or lactating.
- Patients not capable to understand or be compliant with the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Functional dyspepsia patients before and after PPI
Pantoprazole 40mg twice daily in functional dyspepsia patients for 4 weeks
|
Pantoprazole 40mg twice daily
Other Names:
|
No Intervention: Healthy controls before PPI
Baseline investigations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effect of PPI on calcium transient amplitudes after electrical stimulation of submucosal neurons in FD
Time Frame: 4 weeks
|
Calcium transient amplitudes after electrical stimulation of interconnecting fiber bundles before and after PPI
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effect of PPI on duodenal mucosal inflammation (assessed by flow cytometry on lamina propria leukocytes) in FD
Time Frame: 4 weeks
|
Duodenal mucosal inflammation as assessed by flow cytometric quantification of immune cell populations in isolated lamina propria leukocytes before and after PPI
|
4 weeks
|
The effect of PPI on systemic inflammation (assessed by inflammatory cytokine levels in plasma) in FD
Time Frame: 4 weeks
|
Systemic inflammation quantified by inflammatory cytokine levels in plasma before and after PPI
|
4 weeks
|
The effect of PPI on symptoms (Patient Assessment of Upper Gastrointestinal Disorders - Symptom severity index [PAGI-SYM]) in FD
Time Frame: 4 weeks
|
PAGI-SYM symptom scores (ranging from 0 [no symptoms] to 5 [very severe symptoms]) before and after PPI
|
4 weeks
|
The effect of PPI on quality of life (Patient Assessment of Upper Gastrointestinal Disorders - Quality of Life [PAGI-QOL]) in FD
Time Frame: 4 weeks
|
PAGI-QOL scores (ranging from 0 [lowest quality of life] to 5 [highest quality of life]) before and after PPI
|
4 weeks
|
The effect of PPI on salivary cortisol in FD
Time Frame: 4 weeks
|
salivary cortisol before and after PPI
|
4 weeks
|
The effect of PPI on stool microbiota (quantitative microbiota profiling [QMP]) in FD
Time Frame: 4 weeks
|
Stool microbiota assessed by quantitative microbiota profiling (QMP) before and after PPI
|
4 weeks
|
The effect of PPI on urine metabolites in FD
Time Frame: 4 weeks
|
urine metabolites before and after PPI
|
4 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Tim Vanuytsel, MD PhD, Universitaire Ziekenhuizen KU Leuven
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- S64807/64847
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Dyspepsia
-
King Chulalongkorn Memorial HospitalRecruiting
-
Wuhan Central HospitalNot yet recruiting
-
Dong-A ST Co., Ltd.Not yet recruitingFunctional DyspepsiaKorea, Republic of
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Zeria PharmaceuticalRecruitingFunctional DyspepsiaJapan
-
Hong Kong Baptist UniversityXiyuan Hospital of China Academy of Chinese Medical SciencesRecruitingFunctional DyspepsiaHong Kong
-
Seoul National University HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Wonju Severance Christian HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedFunctional DyspepsiaKorea, Republic of
-
Children's Mercy Hospital Kansas CityCompletedFunctional DyspepsiaUnited States
Clinical Trials on Pantoprazole 40mg
-
AstraZenecaCompletedGastroesophageal Reflux DiseaseUnited States, Puerto Rico
-
Alexandria UniversityCompletedPortal Hypertension | Variceal Hemorrhage | Ulcer HemorrhageEgypt
-
Assiut UniversityUnknownProton Pump Inhibitor Allergy
-
University of Auckland, New ZealandCompletedBreast Cancer | Chemotherapy-induced Nausea and Vomiting | OncologyNew Zealand
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
University of Medicine and Pharmacy at Ho Chi Minh...CompletedGastroesophageal RefluxVietnam
-
Future University in EgyptAin Shams University; Nasser Institute For Research and TreatmentCompletedKidney Transplant; Complications
-
Tel-Aviv Sourasky Medical CenterTel Aviv Medical CenterCompletedCoronary Heart Disease | GI BleedingIsrael
-
Daewoong Pharmaceutical Co. LTD.CompletedErosive EsophagitisKorea, Republic of
-
South China Center For Innovative PharmaceuticalsXiangya Hospital of Central South UniversityCompleted